Kraftig neutropeni (< 500 celler/ mm3) forekom hos henholdsvis 20% og 39% af patienterne under det første behandlingsforløb og hele behandlingsperioden.
Severe neutropenia (< 500 cells/ mm3) occurred in 20% and 39% of patients during the first course of treatment and the entire treatment period respectively.